|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
57,860,000 |
Market
Cap: |
223.34(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.47 - $11.89 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 14.8 |
Insider 6 Months : 14.8 |
Insider 3/6 Months : 29.9 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies designed to treat immune-mediated diseases. Co.'s primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. Co. has additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases. Co. has rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection, for the prevention of PVR, a retinal disease, and primary vitreoretinal lymphoma, a rare cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
682,265 |
682,265 |
682,265 |
2,150,494 |
Total Buy Value |
$2,768,372 |
$2,768,372 |
$2,768,372 |
$11,311,413 |
Total People Bought |
1 |
1 |
1 |
3 |
Total Buy Transactions |
5 |
5 |
5 |
17 |
Total Shares Sold |
250,945 |
250,945 |
3,007,444 |
3,007,444 |
Total Sell Value |
$805,803 |
$805,803 |
$5,259,111 |
$5,259,111 |
Total People Sold |
3 |
3 |
4 |
4 |
Total Sell Transactions |
7 |
7 |
9 |
9 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Brady Todd C |
President and CEO |
|
2018-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
101,269 |
302,483 |
|
- |
|
Tulipano Stephen J |
Chief Financial Officer |
|
2017-12-29 |
4 |
A |
$4.00 |
$12,596 |
D/D |
3,153 |
8,563 |
|
- |
|
Clark David J |
Chief Medical Officer |
|
2017-12-29 |
4 |
A |
$4.00 |
$19,072 |
D/D |
4,774 |
4,774 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2017-09-19 |
4 |
B |
$7.25 |
$1,450,000 |
I/I |
200,000 |
3,085,458 |
1.5 |
- |
|
Tulipano Stephen J |
Chief Financial Officer |
|
2017-06-30 |
4 |
A |
$3.95 |
$8,209 |
D/D |
2,077 |
5,410 |
|
- |
|
Brady Todd C |
President and CEO |
|
2017-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
136,806 |
201,214 |
|
- |
|
Tulipano Stephen J |
Chief Financial Officer |
|
2017-02-17 |
4 |
B |
$4.50 |
$14,999 |
D/D |
3,333 |
3,333 |
2.74 |
- |
|
Bronstein Ben |
Director |
|
2017-02-17 |
4 |
B |
$4.50 |
$19,998 |
D/D |
4,444 |
16,944 |
2.39 |
- |
|
Joyce Martin Joseph |
Director |
|
2017-02-17 |
4 |
B |
$4.50 |
$19,998 |
D/D |
4,444 |
17,944 |
2.39 |
- |
|
Brady Todd C |
President and CEO |
|
2017-02-17 |
4 |
B |
$4.50 |
$100,004 |
D/D |
22,223 |
64,408 |
2.81 |
- |
|
Douglas Richard |
Director |
|
2017-02-17 |
4 |
B |
$4.50 |
$180,000 |
D/D |
40,000 |
40,000 |
2.39 |
- |
|
Perceptive Life Sciences Master Fund Ltd |
10% Owner |
|
2017-02-14 |
4 |
B |
$4.50 |
$4,018,613 |
I/I |
893,025 |
2,589,451 |
1.5 |
- |
|
Perceptive Life Sciences Master Fund Ltd |
10% Owner |
|
2016-05-26 |
4 |
B |
$5.00 |
$3,500,000 |
I/I |
700,000 |
1,940,458 |
1.5 |
- |
|
Perceptive Life Sciences Master Fund Ltd |
10% Owner |
|
2015-10-28 |
4 |
B |
$6.50 |
$293,150 |
I/I |
45,100 |
1,240,458 |
1.5 |
- |
|
Perceptive Life Sciences Master Fund Ltd |
10% Owner |
|
2015-10-26 |
4 |
B |
$6.46 |
$323,150 |
I/I |
50,000 |
1,195,358 |
1.5 |
- |
|
Perceptive Life Sciences Master Fund Ltd |
10% Owner |
|
2015-10-22 |
4 |
B |
$6.47 |
$116,661 |
I/I |
18,020 |
1,145,358 |
1.5 |
- |
|
Perceptive Life Sciences Master Fund Ltd |
10% Owner |
|
2015-10-20 |
4 |
B |
$6.30 |
$237,193 |
I/I |
37,145 |
1,127,338 |
1.5 |
- |
|
Edelman Joseph |
10% Owner |
|
2015-10-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,090,193 |
|
- |
|
Shah Nimesh |
10% Owner |
|
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,358 |
|
- |
|
Joyce Martin Joseph |
Director |
|
2014-08-07 |
4 |
B |
$3.95 |
$3,948 |
D/D |
1,000 |
13,500 |
2.31 |
- |
|
Clarke C. Boyd |
Director |
|
2014-08-06 |
4 |
B |
$3.69 |
$11,059 |
D/D |
3,000 |
15,500 |
2.39 |
- |
|
Walker Neal |
Director |
|
2014-05-07 |
4 |
B |
$8.00 |
$50,000 |
D/D |
6,250 |
6,250 |
2.39 |
- |
|
Bronstein Ben |
Director |
|
2014-05-07 |
4 |
B |
$8.00 |
$100,000 |
D/D |
12,500 |
12,500 |
2.39 |
- |
|
Phillips Gary M |
Director |
|
2014-05-07 |
4 |
B |
$8.00 |
$75,000 |
D/D |
9,375 |
9,375 |
2.39 |
- |
|
Clarke C. Boyd |
Director |
|
2014-05-07 |
4 |
B |
$8.00 |
$100,000 |
D/D |
12,500 |
12,500 |
2.39 |
- |
|
103 Records found
|
|
Page 4 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|